Study Shows TIL-Based Biomarker Could Predict Checkpoint Inhibitor Response in NSCLC

An AI-based test developed by South Korean biotech Lunit may improve identification of best responders to immunotherapy when used alongside PD-L1 testing.

Related Keywords

China ,Seoul ,Soult Ukpyolsi ,South Korea ,South Korean ,Hoon Lee ,Tony Mok ,Merck Keytruda ,Bristol Myers Squibb Opdivo ,Genentech Tecentriq ,Sungkyunkwan University Samsung Medical Center ,Samsung Medical Center ,Sungkyunkwan University ,Seoul National University Bundang Hospital ,Drug Administration ,Chinese University Of Hong Kong ,Sungkyunkwan University School Of Medicine ,Lunit Scope ,Clinical Oncology ,Chinese University ,Hong Kong ,Yoon La Choi ,Se Hoon Lee ,Cancer Genome Atlas ,Seoul National University ,Seoul National University Bundang ,Bristol Myers Squibb ,Sungkyunkwan University School ,Chan Young Ock ,